Introduction
============

Lung cancer is one of the most common human malignant tumors and is the leading cause of cancer-related deaths in the world.[@b1-ott-9-6977] Based on global cancer statistics, \~1,824,700 new cases of lung cancer were clinically diagnosed, with an estimated 1,589,900 deaths in 2012.[@b1-ott-9-6977] Human lung cancer consists of two major types: small-cell lung cancer and non-small-cell lung cancer (NSCLC). NSCLC is the most common type and accounts for 85% of lung cancer cases, including adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and adenosquamous carcinoma.[@b2-ott-9-6977],[@b3-ott-9-6977] Due to the lack of an early diagnostic method, \>40% of NSCLC patients have developed metastases by the time of diagnosis,[@b4-ott-9-6977] and the average 5-year survival rate is currently 18%.[@b5-ott-9-6977] Therefore, early diagnosis is crucial for improving the survival rate.[@b6-ott-9-6977]

Epigenetic modifications are involved in humor cancers, DNA methylation, as a crucial mechanism of epigenetic changes, leads to target gene silencing, and plays a key role in the carcinogenesis and progression of cancer.[@b7-ott-9-6977]--[@b9-ott-9-6977] A large number of studies have reported that genes with aberrant promoter methylation are significantly correlated with lung cancer.[@b10-ott-9-6977]--[@b13-ott-9-6977] Located on the human chromosome 9p21, the INK4/ARF locus encodes three cell-cycle inhibitory proteins involving *p15^INK4B^*, *p14^ARF^*, and *p16^INK4A^*; *p16^INK4A^* is encoded by cyclin-dependent kinase inhibitor 2A (*CDKN2A*), *p14^ARF^* is encoded by an alternative reading frame of CDKN2A, and *p15^INK4B^* is encoded by cyclin-dependent kinase inhibitor 2B (*CDKN2B*), which plays roles in the regulation of p53 and retinoblastoma pathways.[@b14-ott-9-6977]--[@b16-ott-9-6977] Inactivation of *p15^INK4B^*, *p14^ARF^*, and *p16^INK4A^* as tumor suppressor genes is one of the most common events in human cancers.[@b17-ott-9-6977]--[@b19-ott-9-6977] The loss of *p15^INK4B^* expression via promoter methylation has been reported in lung cancer cell lines.[@b20-ott-9-6977] Seike et al reported that aberrant methylation of *p15^INK4B^* was not detected in lung cancer tissues.[@b21-ott-9-6977] Wang et al reported that aberrant DNA methylation may be the most common mechanism of inactivating cancer-related genes in lung cancer, including *p15^INK4B^*.[@b22-ott-9-6977] Yanagawa et al reported that aberrant promoter methylation of *p14^ARF^* was correlated with lung cancer.[@b23-ott-9-6977] Zhang et al reported that *p14^ARF^* promoter methylation was not correlated with lung cancer.[@b24-ott-9-6977]

Thus, there were also contradictory results concerning the methylation frequency of *p14^ARF^* and *p15^INK4B^* promoter in lung cancer samples. The current study was first analyzed to better identify the association between *p14^ARF^* and *p15^INK4B^* promoter methylation and lung cancer.

Materials and methods
=====================

Search for eligible studies
---------------------------

A systematic search was performed through online literature databases (PubMed, EMBASE, EBSCO, Wangfang, and Cochrane Library). The following search strategy was used: "methylation," "hypermethylation," or "promoter methylation"; and "lung cancer," "lung carcinoma," or "lung tumor"; and "*p14*," "*p14^ARF^*," "*p15*," "*p15^INK4B^*," "CDKN2B," "cyclin-dependent kinase inhibitor 2." The search was updated till June 24, 2016. Additionally, we manually searched the references of the selected studies to obtain additional studies. The full texts of all of the qualified studies were published.

Inclusion criteria
------------------

Studies were included if they met all the following criteria: 1) Study was an original case-control study on the association between *p14^ARF^* or *p15^INK4B^* gene promoter methylation and lung cancer; 2) Patients were diagnosed as lung cancer based on histopathological examination; 3) Study had sufficient data to calculate the pooled odds ratios (ORs) or hazard ratios (HRs) and 95% confidence intervals (CIs) for the meta-analysis; and 4) The most recent study with more information was selected when several publications contained duplicated data.

Data extraction
---------------

The data obtained from the publications included first author's name, year of publication, country, ethnicity, sample type, methylation detection method, histology, number of participants, overall survival (OS), and methylation frequency. The various sample types included tissue, bronchoalveolar lavage fluid (BALF), and blood samples, clinicopathological parameters, such as gender status, smoking status, tumor differentiation, and tumor stage. The selection of eligible studies and data extraction were independently performed by two reviewers (LY and WD).

Statistical analysis
--------------------

The current meta-analysis was performed using the STATA software (version 12.0, Stata Corporation, College Station, TX, USA). The pooled ORs and 95% CIs were calculated to determine the correlation between *p14^ARF^* or *p15^INK4B^* gene promoter methylation and lung cancer. The pooled HR with 95% CI was used to evaluate the impact of *p14^ARF^* promoter methylation on OS of NSCLC patients. Between-study heterogeneity was estimated based on the Cochran's *Q*-test and *I*^2^ statistic.[@b25-ott-9-6977] A random-effects model was applied for the meta-analysis with significant heterogeneity (*I*^2^\>50% and *P*\<0.1); otherwise, the fixed-effects model was used.[@b26-ott-9-6977],[@b27-ott-9-6977] *P*-value \<0.05 was considered to be significant.

Results
=======

Study characteristics
---------------------

As shown in [Figure 1](#f1-ott-9-6977){ref-type="fig"}, 269 potentially relevant articles were obtained from the PubMed, EMBASE, EBSCO, Wangfang, and Cochrane Library databases. After a series of selection procedures, a total of 12 studies involving 625 lung cancer samples and 488 nontumor samples were included in the current study. Eight studies with 505 NSCLC samples and 419 nontumor samples analyzed the relationship between *p14^ARF^* promoter methylation and NSCLC.[@b23-ott-9-6977],[@b24-ott-9-6977],[@b28-ott-9-6977]--[@b33-ott-9-6977] Of 8 studies, 7 studies used methylation-specific polymerase chain reaction and 1 study used quantitative fluorogenic real-time polymerase chain reaction. Four studies with 120 lung cancer samples and 69 nontumor samples evaluated the relationship between *p15^INK4B^* promoter methylation and lung cancer.[@b21-ott-9-6977],[@b22-ott-9-6977],[@b34-ott-9-6977],[@b35-ott-9-6977] Of 4 studies, 3 studies used methylation-specific polymerase chain reaction detection and 1 study used 3-dimensional, polyacrylamide gel-based DNA microarray coupled with linker-polymerase chain reaction. Four studies evaluated the correlation of *p14^ARF^* promoter methylation with clinicopathological features.[@b23-ott-9-6977],[@b30-ott-9-6977],[@b32-ott-9-6977],[@b33-ott-9-6977] Two studies assessed the correlation of *p15^INK4B^* promoter methylation with clinicopathological features.[@b22-ott-9-6977],[@b34-ott-9-6977] The general characteristics of the included studies are presented in [Table 1](#t1-ott-9-6977){ref-type="table"}.

Promoter methylation of *p14^ARF^* and *p15^INK4B^* in lung cancer
------------------------------------------------------------------

Substantial heterogeneity among studies was not detected (*p14^ARF^*: *I*^2^=0.0%, *P*=0.900; *p15^INK4B^*: *I*^2^=0.0%, *P*=0.992), as shown in [Figures 2](#f2-ott-9-6977){ref-type="fig"} and [3](#f3-ott-9-6977){ref-type="fig"}, indicating that our results were stable and reliable, with no evidence of heterogeneity. The pooled OR from 8 studies with 505 NSCLC samples and 419 nontumor samples showed that *p14^ARF^* promoter methylation status was significantly higher in NSCLC than in nontumor samples (OR =4.94, 95% CI: 2.79--8.76, *P*\<0.001) ([Figure 2](#f2-ott-9-6977){ref-type="fig"}), which suggested that *p14^ARF^* promoter methylation may play a key role in the initiation of NSCLC. The pooled OR from 4 studies involving 120 lung cancer samples and 69 nontumor samples demonstrated that *p15^INK4B^* promoter methylation status had a similar OR among lung cancer and nontumor samples (OR =2.76, 95% CI: 0.46--16.70, *P*=0.27) ([Figure 3](#f3-ott-9-6977){ref-type="fig"}), indicating that *p15^INK4B^* promoter methylation was not significantly associated with a risk of lung cancer.

Subgroup analyses of *p14^ARF^* promoter methylation
----------------------------------------------------

Subgroup analyses based on the ethnic population (Asian population and Caucasian population) and sample type (tissue, BALF, and blood) were analyzed to find the different strength of association. Subgroup analysis of ethnicity revealed that *p14^ARF^* promoter methylation was significantly correlated with an increased risk of NSCLC in Asians and Caucasians (OR =4.54, 95% CI: 2.47--8.32, *P*\<0.001; OR =8.05, 95% CI: 1.39--46.50, *P*=0.02; respectively) ([Figure 4](#f4-ott-9-6977){ref-type="fig"}). Subgroup analysis of sample type demonstrated that *p14^ARF^* promoter methylation had a significantly increased risk of NSCLC in tissue samples (OR =4.55, 95% CI: 2.54--8.18, *P*\<0.001), but not in BALF and blood samples ([Figure 5](#f5-ott-9-6977){ref-type="fig"}). The results of BALF and blood samples should be carefully considered using smaller sample sizes.

Prognostic value of *p14^ARF^* promoter methylation
---------------------------------------------------

The pooled HR from 1 study with 92 NSCLC patients demonstrated that *p14^ARF^* promoter methylation was not significantly correlated with OS of patients with NSCLC (HR =0.57, 95% CI: 0.19--1.73).[@b29-ott-9-6977] Additional studies with larger subjects are needed to assess the correlation between *p14^ARF^* promoter methylation and OS in NSCLC in the future.

Association of *p14^ARF^* and *p15^INK4B^* promoter methylation with clinicopathological features
-------------------------------------------------------------------------------------------------

We determined whether *p14^ARF^* and *p15^INK4B^* promoter methylation was associated with clinicopathological characteristics, including four studies with 259 NSCLC patients and 2 studies with 73 patients with NSCLC, respectively. Our results showed that aberrant promoter methylation of *p14^ARF^* was not correlated with clinicopathological characteristics (*P*\>0.05), including tumor stage, tumor histology, gender status, tumor differentiation, smoking status, and lymph node status ([Figure 6](#f6-ott-9-6977){ref-type="fig"}). Aberrant promoter methylation of *p15^INK4B^* was also not associated with clinicopathological features (*P*\>0.05), including gender status, tumor histology, tumor differentiation, and tumor stage ([Figure 7](#f7-ott-9-6977){ref-type="fig"}).

Discussion
==========

Tumor suppressor genes *p16^INK4A^*, *p14^ARF^*, and *p15^INK4B^* encoding cell-cycle regulatory proteins play a crucial role in the negative regulation of the cell cycle and the inhibition of the cell proliferation.[@b36-ott-9-6977] The silencing of *p16^INK4A^*, *p14^ARF^*, and *p15^INK4B^* genes by DNA methylation of the C-phosphate-G (CpG) islands of the promoter regions has been reported to be involved in the carcinogenesis and be an early biologic event in many cancers.[@b37-ott-9-6977]--[@b40-ott-9-6977] Based on a meta-analysis, Gu et al reported that *p16^INK4A^* promoter methylation may play a key role in the tumorigenesis of lung cancer.[@b41-ott-9-6977] However, whether *p14^ARF^* or *p15^INK4B^* promoter methylation plays a crucial role in the carcinogenesis of lung cancer, which remains to be certified. The results were inconsistent with regard to *p14^ARF^* and *p15^INK4B^* promoter methylation rate in lung cancer. For example, Topaloglu et al reported that *p14^ARF^* promoter was absent in methylation in NSCLC.[@b30-ott-9-6977] Fischer et al reported that *p14^ARF^* promoter had a methylation frequency of 30.4% in NSCLC.[@b29-ott-9-6977] In addition, Seike et al showed that *p15^INK4B^* promoter had no methylation,[@b21-ott-9-6977] while Chaussade et al showed that *p15^INK4B^* promoter had a methylation rate of 100% in lung cancer.[@b35-ott-9-6977] Therefore, we performed a meta-analysis to evaluate the strength of *p14^ARF^* and *p15^INK4B^* promoter methylation on lung cancer risk.

There was no evidence of the heterogeneity in the current meta-analysis, presenting no obvious publication bias. Our findings demonstrated that *p14^ARF^* promoter methylation status had a significantly higher OR in NSCLC than in nontumor samples, while significant correlation was not observed between *p15^INK4B^* promoter methylation and lung cancer, suggesting that *p14^ARF^* promoter methylation may play an important role in the initiation of NSCLC. However, the result of *p15^INK4B^* promoter methylation should be prudent as only 120 lung cancer samples were included in our analysis.

Next, subgroup analyses of the ethnic population (Asians and Caucasians) and sample type (tissue, BALF, and blood) were conducted to find the different association between *p14^ARF^* promoter methylation and different subgroups in NSCLC versus nontumor samples. Significant correlation between Asian population and Caucasian population in *p14^ARF^* promoter methylation was found in subgroup analysis of ethnicity, which suggested that Asian and Caucasian populations were susceptible to *p14^ARF^* promoter methylation. According to subgroup analysis of sample type, a significant association between *p14^ARF^* promoter methylation and NSCLC was observed in tissue subgroup, but not in BALF and blood subgroups. The results should be carefully considered as only one or two studies with smaller subjects were analyzed in BALF and blood subgroups.

Previous several meta-analyses had evaluated the correlation of *p16^INK4A^* methylation with clinicopathological parameters in lung cancer,[@b11-ott-9-6977],[@b42-ott-9-6977],[@b43-ott-9-6977] which suggested that *p16^INK4A^* methylation was associated with smoking status and tumor histology. However, the correlation of *p14^ARF^* and *p15^INK4B^* promoter methylation with clinicopathological features was not determined. Our findings suggested that *p14^ARF^* and *p15^INK4B^* promoter methylation was not correlated with clinicopathological characteristics, such as gender status, tumor histology, tumor differentiation, and tumor stage. Based on small sample sizes (*p14^ARF^*: 259 NSCLC patients, *p15^INK4B^*: 73 patients with NSCLC), more studies with larger sample size should be done in the future.

Limitations
===========

There were several limitations in the present meta-analysis. First, there might be selection bias because eligible studies were restricted to articles published in English and Chinese, studies with other language and other styles, such as conference abstracts were missed. Second, the main ethnic population consisted of Asian and Caucasian populations, and other ethnicities, such as Africans, were insufficient. Third, only smaller subjects were included in BALF and blood subgroups; more studies with larger sample sizes are essential to further determine whether *p14^ARF^* promoter methylation can become a promising biomarker based on BALF or blood detection. Fourth, only 1 study reported that *p14^ARF^* promoter methylation was not associated with the prognosis of NSCLC patients in OS; further large-scale studies with larger subjects are very necessary in the future. Finally, sample sizes on clinicopathological features were smaller in this study.

Conclusion
==========

The results suggested that *p14^ARF^* promoter methylation may play a pivotal role in the carcinogenesis of lung cancer, but not *p15^INK4B^* promoter methylation. In addition, *p14^ARF^* promoter methylation was a susceptible gene for Asians and Caucasians. Aberrant promoter methylation of *p14^ARF^* and *p15^INK4B^* was not associated with clinicopathological features. Additional studies with larger subjects are needed to further validate our results.
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![Flow diagram of the stepwise selection from relevant studies.](ott-9-6977Fig1){#f1-ott-9-6977}

![The pooled OR from eight studies with 505 NSCLC samples and 419 nontumor samples showing the association between *p14^ARF^* promoter methylation and NSCLC in cancer versus nontumor samples, *I*^2^=0%, OR =4.54, 95% CI: 2.47--8.32, *P*\<0.001.\
**Abbreviations:** CI, confidence interval; NSCLC, non-small-cell lung cancer; OR, odds ratio.](ott-9-6977Fig2){#f2-ott-9-6977}

![The pooled OR from four studies with 120 lung cancer samples and 69 nontumor samples showing the relationship between *p15^INK4B^* promoter methylation and lung cancer in cancer versus nontumor samples, *I*^2^=0%, OR =2.76, 95% CI: 0.46--16.70, *P*=0.27.\
**Abbreviations:** CI, confidence interval; OR, odds ratio.](ott-9-6977Fig3){#f3-ott-9-6977}

![The pooled OR based on subgroup analysis of ethnicity showing the correlation between *p14^ARF^* promoter methylation and different ethnicity in cancer versus nontumor samples, Asians: OR =4.54, 95% CI: 2.47--8.32, *P*\<0.001; Caucasians: OR =8.05, 95% CI: 1.39--46.50, *P*=0.02.\
**Abbreviations:** CI, confidence interval; OR, odds ratio.](ott-9-6977Fig4){#f4-ott-9-6977}

![The pooled OR based on subgroup analysis of sample type showing the correlation between *p14^ARF^* promoter methylation and different sample type in cancer versus nontumor samples, tissue: OR =4.55, 95% CI: 2.54--8.18, *P*\<0.001; BALF: unmethylation; blood: OR =12.81, 95% CI: 0.74--222.29, *P*=0.08.\
**Abbreviations:** BALF, bronchoalveolar lavage fluid; CI, confidence interval; OR, odds ratio; NA, not applicable.](ott-9-6977Fig5){#f5-ott-9-6977}

![The pooled OR from four studies with 259 NSCLC samples showing the association of *p14^ARF^* promoter methylation with clinicopathological characteristics, including tumor stage, tumor histology, gender status, tumor differentiation, smoking status, and lymph node status (all *P*\>0.05).\
**Abbreviations:** AC, adenocarcinoma; CI, confidence interval; NSCLC, non-small-cell lung cancer; OR, odds ratio; SCC, squamous cell carcinoma; NA, not applicable.](ott-9-6977Fig6){#f6-ott-9-6977}

![The pooled OR from two studies with 73 NSCLC samples showing the association of *p15^INK4B^* promoter methylation with clinicopathological characteristics, including gender status, tumor histology, tumor differentiation, and tumor stage (all *P*\>0.05).\
**Abbreviations:** CI, confidence interval; NSCLC, non-small-cell lung cancer; OR, odds ratio; NA, not applicable.](ott-9-6977Fig7){#f7-ott-9-6977}

###### 

The general characteristics of the included studies in the current meta-analysis

  Gene                                      First author                               Country      Ethnicity    Method   Histology   Sample   Cancer   Control   OS                        
  ----------------------------------------- ------------------------------------------ ------------ ------------ -------- ----------- -------- -------- --------- ----- ------------------- --
  *p14^ARF^*                                Jarmalaite et al[@b31-ott-9-6977] (2003)   Finland      Caucasians   MSP      NSCLC       Tissue   8.7      46        2     51                  
  Topaloglu et al[@b30-ott-9-6977] (2004)   USA                                        Caucasians   QRTPCR       NSCLC    BALF        0        31       0         10                        
  Fischer et al[@b29-ott-9-6977] (2007)     Germany                                    Caucasians   MSP          NSCLC    Blood       30.4     92       0         14    0.57 (0.19--1.73)   
  Yanagawa et al[@b23-ott-9-6977] (2007)    Japan                                      Asians       MSP          NSCLC    Tissue      7.9      101      0.99      101                       
  De Jong et al[@b28-ott-9-6977] (2009)     the Netherlands                            Caucasians   MSP          NSCLC    BALF        0        10       0         18                        
  Zhang et al[@b24-ott-9-6977] (2011)       China                                      Asians       MSP          NSCLC    Tissue      6.4      78       1.3       78                        
  Tian et al[@b32-ott-9-6977] (2006)        China                                      Asians       MSP          NSCLC    Tissue      17.5     40       2.5       40                        
  Hu et al[@b33-ott-9-6977] (2014)          China                                      Asians       MSP          NSCLC    Tissue      33.6     107      12.1      107                       
  *p15^INK4B^*                              Chaussade et al[@b35-ott-9-6977] (2001)    France       Caucasians   MSP      NELC        Tissue   100      20        95    20                  
  Seike et al[@b21-ott-9-6977] (2000)       Japan                                      Asians       MSP          LC       Tissue      0        27       0         27                        
  Shimamoto et al[@b34-ott-9-6977] (2004)   Japan                                      Asians       MSP          NSCLC    Tissue      11.1     45       0         10                        
  Wang et al[@b22-ott-9-6977] (2008)        China                                      Asians       3DPCR        NSCLC    Tissue      7.1      28       0         12                        

**Note:**

Total is the number of lung cancer or nontumor samples.

**Abbreviations:** 3DPCR, 3-dimensional (3-D), polyacrylamide gel-based DNA microarray coupled with linker-polymerase chain reaction; BALF, bronchoalveolar lavage fluid; LC, lung cancer; M+, methylation positive status; MSP, methylation-specific polymerase chain reaction; NELC, neuroendocrine lung cancer; NSCLC, non-small-cell lung cancer; OS, overall survival; QRTPCR, quantitative fluorogenic real-time PCR.
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